Dr Reddy's anounces collaboration with Amgen

The collaboration leverages the capabilities of both companies, combining three of Amgen's innovative therapies with Dr. Reddy's deep understanding of patient and physician needs in India.

Dr. Reddy's Laboratories announced that it has entered into a strategic collaboration with Amgen - one of the world's leading independent biotechnology companies - to market and distribute three Amgen medicines in India in the areas of oncology and cardiology. Under the terms of the collaboration, Dr. Reddy's shall perform a full range of regulatory and commercial services to seek approval and launch Kyprolis (carfilzomib), BLINCYTO (blinatumomab) and Repatha (evolocumab) in India. The collaboration leverages the capabilities of both companies, combining three of Amgen's innovative therapies with Dr. Reddy's deep understanding of patient and physician needs in India.

Dr. Reddy's Executive Vice President and Head of lndfa Business & Global Business Development Alok Sonig stated, "We are excited about our strategic collaboration with an innovation powerhouse like Amgen and look forward to making their innovative medicines accessible to Indian patients. Addressing significant unmet needs of patients in oncology and cardiovascular are key areas in India and, therefore, a priority for us at Dr. Reddy's. We believe that good health can't wait and that this is an important milestone for us in our journey as we improve patient  care."

"We are pleased to be joining forces with Dr. Reddy's Laboratories  in order to make Amgen's innovative medicines available to patients in India," said Penny Wan, Amgen vice president and general manager, Japan Asia Pacific  Region. "Dr. Reddy's has significant experience serving oncology and cardiovascular patients in India and shares Amgen's interest in delivering  new treatment  options to seriously ill patients."